Crescent Biopharma CBIO
NASDAQ CBIO
$14.32 +0.06 (+0.42%)
At close: Oct 2, 2026 · 4:00 PM EDT

Crescent Biopharma (CBIO) Gains from Sales and Divestitures (2021 - 2024)

Updated

Crescent Biopharma (CBIO) posted Gains from Sales and Divestitures of $30,000 for Q4 2024.

Analysis

Crescent Biopharma (CBIO) Gains from Sales and Divestitures (2021 - 2024) Analysis & Trends

For FY2024, Crescent Biopharma's Gains from Sales and Divestitures came in at -$46,654.

  • In prior years, Crescent Biopharma's Gains from Sales and Divestitures was -$8,627 in FY2023, -$3,498 in FY2022 and -$2,174 in FY2021.
  • The Q4 2024 figure stands as the lowest quarterly Gains from Sales and Divestitures since Q1 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Crescent Biopharma 397.47 Mn -309.83 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 30,000.00
Mar 31, 2021 -2,174.00
API Access

Crescent Biopharma Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CBIO&period=max&api_key=YOUR_API_KEY